Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07623616 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia
Trial Details
NCT Number NCT07623616
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions
(from sponsor)		 Acute Myeloid Leukemia (AML)
Related terms Leukemia, Myeloid, Acute
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov